Malta - English - Medicines Authority

mylan ire healthcare limited unit 35/36, grange parade, baldoyle industrial estate, dublin 13, ireland - dydrogesterone, estradiol - film-coated tablet - dydrogesterone 5 mg estradiol 1 mg - sex hormones and modulators of the genital system

Australia - English - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - estradiol, quantity: 1 mg (equivalent: estradiol hemihydrate, qty 1.03 mg); dydrogesterone, quantity: 5 mg - tablet, film coated - excipient ingredients: lactose monohydrate; maize starch; hypromellose; magnesium stearate; colloidal anhydrous silica; titanium dioxide; iron oxide yellow; iron oxide red; macrogol 400 - hormone replacement therapy (hrt) in oestrogen deficiency associated with natural or artificial menopause in women with an intact uteri. prevention of postmenopausal bone mineral density loss in women. for initiation and continuation of treatment of postmenopausal symptoms, the lowest possible effective dose for the shortest duration should be used with the goal being short term use.

Malta - English - Medicines Authority

mylan ire healthcare limited unit 35/36, grange parade, baldoyle industrial estate, dublin 13, ireland - dydrogesterone, estradiol - film-coated tablet - dydrogesterone 2.5 mg estradiol 0.5 mg - sex hormones and modulators of the genital system

Israel - English - Ministry of Health

abbott medical laboratories ltd, israel - dydrogesterone; estradiol as hemihydrate - film coated tablets - dydrogesterone 5 mg; estradiol as hemihydrate 1 mg - dydrogesterone and estrogen - hormone replacement therapy (hrt) for estrogen deficiency symptoms in postmenopausal women at least 12 months since last menses.prevention of osteoporosis in postmenopausal women at high risk of future fractures. femoston contini 1/5 should only be used in patients who are intolerant of other products, approved for the prevention of osteoporosis or for whom these products are contra-indicated.femoston is indicated for women with an intact uterus

Ireland - English - HPRA (Health Products Regulatory Authority)

laboratorios leon farma, s.a. - ethinylestradiol; drospirenone - film-coated tablet - 0.03/3 milligram(s) - progestogens and estrogens, fixed combinations; drospirenone and ethinylestradiol

Canada - English - Health Canada

pharmascience inc - estradiol - tablet - 0.5mg - estradiol 0.5mg - estrogens

Canada - English - Health Canada

pharmascience inc - estradiol - tablet - 1mg - estradiol 1mg - estrogens

Canada - English - Health Canada

pharmascience inc - estradiol - tablet - 2mg - estradiol 2mg - estrogens

United States - English - NLM (National Library of Medicine)

pharmacia & upjohn company llc - estradiol cypionate (unii: 7e1dv054lo) (estradiol - unii:4ti98z838e) - estradiol cypionate 5 mg in 1 ml - depo-estradiol injection is indicated in the treatment of: estrogens should not be used in individuals with any of the following conditions: there appears to be little or no increased risk of birth defects in children born to women who have used estrogens and progestins from oral contraceptives inadvertently during early pregnancy. (see precautions.) chlorobutanol anhydrous (chloral derivative) added as a preservative may be habit forming.

United States - English - NLM (National Library of Medicine)

physicians total care, inc. - estradiol cypionate (unii: 7e1dv054lo) (estradiol cypionate - unii:7e1dv054lo) - estradiol cypionate 5 mg in 1 ml - depo-estradiol injection is indicated in the treatment of: - moderate to severe vasomotor symptoms associated with the menopause. - hypoestrogenism due to hypogonadism. estrogens should not be used in individuals with any of the following conditions: - undiagnosed abnormal genital bleeding. - known or suspected cancer of the breast. - known or suspected estrogen-dependent neoplasia. - active deep vein thrombosis, pulmonary embolism or history of these conditions. - active or recent (e.g., within the past year) arterial thromboembolic disease (e.g., stroke, myocardial infarction). - liver dysfunction or disease. - depo-estradiol should not be used in patients with known hypersensitivity to its ingredients. - known or suspected pregnancy. there is no indication for depo-estradiol in pregnancy. there appears to be little or no increased risk of birth defects in children born to women who have used estrogens and progestins from oral contraceptives inadvertently during early pregnancy. (see precautions.) chlorobu